Cognition Therapeutics

Q3 FY2026 EarningsQ3 FY26 results beat consensus on profitability, with a net loss of $4.1M compared to the $6.0M loss expected. Diluted EPS was -$0.04, outperforming the -$0.07 mean estimate. While operating expenses rose to $7.4M due to increased R&D for the zervimesine clinical programs, higher-than-expected grant income of $3.0M effectively narrowed the bottom-line gap. Management confirmed a cash runway into Q4 2027, alleviating immediate liquidity concerns as the company awaits Phase 2 START results in 2H 2027.